{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:02:17Z","timestamp":1785423737584,"version":"3.56.0"},"reference-count":107,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Direct oral anticoagulants (DOACs) have transformed the landscape of antithrombotic therapy in the past two decades. However, there is uncertainty about when they should or should not be used for treatment or prevention of thromboembolic events. DOACs have largely replaced warfarin for many patients with atrial fibrillation or venous thromboembolism who require anticoagulant therapy. In addition to noninferior efficacy, fewer drug\u2013drug and food\u2013drug interactions and improved convenience; DOACs have been shown to reduce the risk of intracranial hemorrhage. They have also received new indications compared with warfarin, such as cardiovascular risk reduction in patients with stable atherosclerotic diseases. However, there are some scenarios in which DOACs are associated with inferior efficacy or worse safety compared with standard treatment, such as warfarin. These include patients with mechanical heart valves, thrombotic antiphospholipid syndrome, and others. Although DOACs offer a streamlined and convenient option for the management of many patients with or at risk of thromboembolic events, their use should be avoided in certain high-risk scenarios. This minireview summarizes such conditions and those in which there is uncertainty for use of DOACs for particular diseases or particular patient subgroups.<\/jats:p>","DOI":"10.1055\/a-2451-4014","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T23:53:22Z","timestamp":1731974002000},"page":"611-617","source":"Crossref","is-referenced-by-count":11,"title":["Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid"],"prefix":"10.1055","volume":"125","author":[{"given":"Antoine","family":"Bejjani","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Yale New Haven Hospital\/Yale Center for Outcomes Research and Evaluation, New Haven, Connecticut, United States"},{"name":"Cardiovascular Research Foundation, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"e0197583","DOI":"10.1371\/journal.pone.0197583","article-title":"Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis","volume":"13","author":"R CP Makam","year":"2018","journal-title":"PLoS One"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"A P Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"9921","key":"ref3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"ref7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"S J Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"ref10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"ref11","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"ref13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"H R B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"ref15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"S Schulman","year":"2013","journal-title":"N Engl J Med"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty","volume":"378","author":"D R Anderson","year":"2018","journal-title":"N Engl J Med"},{"issue":"9717","key":"ref18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"M R Lassen","year":"2010","journal-title":"Lancet"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"T Fuji","year":"2014","journal-title":"Thromb Res"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"B I Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"26","key":"ref21","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"M R Lassen","year":"2010","journal-title":"N Engl J Med"},{"issue":"9591","key":"ref22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"B I Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial","volume":"105","author":"B I Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"issue":"26","key":"ref24","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"B I Eriksson","year":"2008","journal-title":"N Engl J Med"},{"issue":"9632","key":"ref25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"A K Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"26","key":"ref26","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"M R Lassen","year":"2008","journal-title":"N Engl J Med"},{"issue":"9676","key":"ref27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"A G Turpie","year":"2009","journal-title":"Lancet"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"J S Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1055\/a-1646-2244","article-title":"Extended-duration low-intensity apixaban to prevent recurrence in patients with provoked venous thromboembolism and enduring risk factors: rationale and design of the HI-PRO Trial","volume":"122","author":"B Bikdeli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"81","author":"C D Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"H Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"V Pengo","year":"2018","journal-title":"Blood"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"J Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"S C Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","article-title":"When direct oral anticoagulants should not be standard treatment: JACC State-of-the-Art Review","volume":"83","author":"A Bejjani","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref36","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"J W Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"07","key":"ref37","first-page":"a2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"T Y Wang","year":"2023","journal-title":"NEJM Evid"},{"issue":"23","key":"ref38","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"S D Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"A S De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"H Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"ref41","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"C P Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"ref42","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"C M Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"P Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"ref44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"R D Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"9683","key":"ref45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"J L Mega","year":"2009","journal-title":"Lancet"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"J L Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"S S Virani","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"S Yasuda","year":"2019","journal-title":"N Engl J Med"},{"issue":"09","key":"ref49","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1055\/s-0042-1744543","article-title":"Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings","volume":"122","author":"H Arashi","year":"2022","journal-title":"Thromb Haemost"},{"issue":"36","key":"ref50","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"C Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1160\/TH-17-10-0709","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE)","volume":"117","author":"G YH Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"G Renda","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"ref53","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"H P Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"J A Joglar","year":"2024","journal-title":"Circulation"},{"issue":"36","key":"ref55","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"I C Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"F I Mulder","year":"2020","journal-title":"Blood"},{"issue":"07","key":"ref57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref58","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref60","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1055\/a-1367-7830","article-title":"Safety of apixaban for cancer-associated thrombosis","volume":"121","author":"B Bikdeli","year":"2021","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref62","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1055\/a-2316-5269","article-title":"Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE Registry-2","volume":"124","author":"D Sueta","year":"2024","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1055\/s-0044-1788997","article-title":"Open issues in the choice and management of direct oral anticoagulants in patients with cancer-related venous thromboembolism","volume":"124","author":"D Pastori","year":"2024","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref64","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"14","key":"ref65","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"ref66","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"M P Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"05","key":"ref67","first-page":"e35","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"143","author":"C M Otto","year":"2021","journal-title":"Circulation"},{"issue":"11","key":"ref68","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"S J Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"e003709","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709","article-title":"Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"M Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"M G Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"ref71","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"N M Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"G D Dangas","year":"2020","journal-title":"N Engl J Med"},{"issue":"29","key":"ref73","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"J P Collet","year":"2022","journal-title":"Eur Heart J"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR Randomized Clinical Trial","volume":"146","author":"D W Park","year":"2022","journal-title":"Circulation"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0042-1760128","article-title":"Direct oral anticoagulants or vitamin K antagonists after TAVR: insights from the ENVISAGE-TAVI AF and ATLANTIS trials","volume":"123","author":"F Oliveri","year":"2023","journal-title":"Thromb Haemost"},{"issue":"23","key":"ref76","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"R G Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref77","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"H C Diener","year":"2019","journal-title":"N Engl J Med"},{"issue":"01","key":"ref78","first-page":"a2300235","article-title":"Apixaban versus aspirin for embolic stroke of undetermined source","volume":"3","author":"T Geisler","year":"2024","journal-title":"NEJM Evid"},{"issue":"07","key":"ref79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial","volume":"331","author":"H Kamel","year":"2024","journal-title":"JAMA"},{"issue":"07","key":"ref80","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"D O Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/a-1745-2083","article-title":"Stroke and thromboembolism in patients with heart failure and sinus rhythm: a matter of risk stratification?","volume":"122","author":"A Rivas","year":"2022","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-0040-1716753","article-title":"Direct oral anticoagulant dosing in extremes of body weight: time to revisit the guidelines?","volume":"121","author":"A K Pandey","year":"2021","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"J S Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"ref84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"P Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"ref85","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"149","author":"W F McIntyre","year":"2024","journal-title":"Circulation"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA","volume":"84","author":"R D Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref87","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcin.2022.01.285","article-title":"Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction","volume":"15","author":"Z Zhang","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"ref88","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial)","volume":"77","author":"M Abdelnabi","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/JCPC.JCPC_41_20","article-title":"Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus","volume":"9","author":"W Isa","year":"2020","journal-title":"J Clin Prev Cardiol"},{"issue":"07","key":"ref90","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ehjcvp\/pvab057","article-title":"Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial","volume":"8","author":"R Alcalai","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"15","key":"ref91","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"G N Levine","year":"2022","journal-title":"Circulation"},{"issue":"05","key":"ref93","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/CIRCULATIONAHA.123.067528","article-title":"A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial","volume":"149","author":"K Hosokawa","year":"2024","journal-title":"Circulation"},{"issue":"12","key":"ref94","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial","volume":"76","author":"J M Ferro","year":"2019","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref95","first-page":"1","article-title":"Use of oral rivaroxaban in cerebral venous thrombosis","volume":"10","author":"M Maqsood","year":"2020","journal-title":"J Drug Assess"},{"issue":"11","key":"ref96","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1161\/STROKEAHA.123.044113","article-title":"Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-care in symptomatic cerebral venous thrombosis","volume":"54","author":"T S Field","year":"2023","journal-title":"Stroke"},{"issue":"04","key":"ref98","doi-asserted-by":"crossref","first-page":"e12517","DOI":"10.1002\/rth2.12517","article-title":"Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): a two-center open-label pilot randomized controlled trial","volume":"5","author":"R Ikesaka","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"ref99","doi-asserted-by":"crossref","first-page":"a2200104","DOI":"10.1056\/EVIDoa2200104","article-title":"Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis","volume":"1","author":"A Plessier","year":"2022","journal-title":"NEJM Evid"},{"issue":"08","key":"ref100","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"K A Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref101","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1055\/s-0039-1697682","article-title":"Venous thromboembolism in patients with liver cirrhosis: findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) registry","volume":"45","author":"B Bikdeli","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"ref102","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"A Qamar","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/a-2021-8910","article-title":"Direct oral anticoagulants in the very elderly","volume":"123","author":"J W Eikelboom","year":"2023","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref104","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"L PT Joosten","year":"2024","journal-title":"Circulation"},{"issue":"04","key":"ref105","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.rpth.2024.102424","article-title":"Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use","volume":"8","author":"C D Khairani","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"36","key":"ref106","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"L Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"issue":"24","key":"ref107","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"H L Gornik","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"ref108","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1055\/s-0043-1770100","article-title":"Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis","volume":"123","author":"Z Li","year":"2023","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref109","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease","volume":"122","author":"A T Cohen","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2451-4014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T22:30:47Z","timestamp":1750804247000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2451-4014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":107,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2451-4014","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}